PropertyValue
?:abstract
  • Thrombotic complications are frequent in COVID-19 and contribute significantly to mortality and morbidity. We review several mechanisms of hypercoagulability in sepsis that may be upregulated in COVID-19. These include immune-mediated thrombotic mechanisms, complement activation, macrophage activation syndrome, antiphospholipid antibody syndrome, hyperferritinemia, and renin-angiotensin system dysregulation. We highlight biomarkers within each pathway with potential prognostic value in COVID-19. Lastly, recent observational studies have evaluated a role for the expanded use of therapeutic anticoagulation in COVID-19. We review strengths and weaknesses of these studies, and we also discuss the hypothetical benefit and anticipated challenges of fibrinolytic therapy in COVID-19. This article is protected by copyright. All rights reserved.
?:creator
?:doi
  • 10.1002/ajh.25982
?:doi
?:journal
  • American_journal_of_hematology
?:license
  • unk
?:pmid
?:pmid
  • 32857878
?:publication_isRelatedTo_Disease
?:source
  • Medline
?:title
  • Thrombosis in COVID-19.
?:type
?:year
  • 2020-08-28

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/fg3nlmhg>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/fg3nlmhg>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all